A Phase IA/II, Multi-center, Open-label Study of HCD122 Administered Intravenously Once Weekly for Four Weeks in Adult Patients With Advanced Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies (CHIR-12.12-LYM-01)

Inclusion Criteria

Inclusion criteria:

Patients may be included in the study if they meet all of the following criteria:

- Patients must have confirmed diagnosis of HL or NHL (follicular, marginal zone /
MALT, diffuse large B-cell, or mantle cell) per REAL/WHO classification

- Patients must have progressed after at least 2 prior therapies (autologous stem cell
transplantation is considered as 1 therapy)

- Patients must be ≥ 18 years

- Patients must have life expectancy > 3 months

- Patient must have adequate laboratory results

- Patients must have WHO Performance Status grade 0, 1, or 2

- Patients must have at least one site of measurable disease

- Patients must have discontinued any previous monoclonal antibody or
radioimmunotherapy, and must have recovered fully from the side effects of that
treatment prior to beginning study treatment.

- Patients must be willing and able to sign the informed consent form and comply with
the study protocol

Exclusion criteria:

Patients will be excluded from the study if they meet any of the following criteria:

- Patients who have been treated with any anti-CD40 antibody

- Patients who have received prior allogeneic stem cell transplant

- Patients who have had a prior anaphylactic or other severe infusion reaction such
that the patient is unable to tolerate human immunoglobulin or monoclonal antibody
administration

- Patients who have history or clinical evidence of central nervous system, meningeal,
or epidural disease including brain metastasis

- Women of child-bearing potential (WCBP) who are pregnant or breast feeding.

Other protocol-defined inclusion/exclusion criteria may apply